1-14 of 14
Kim Cocks
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R 2 -CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQoL) Analysis of the International Robust Study

Annalisa Chiappella, Thomas E. Witzig, MD, Kim Cocks, Mike Greenwood, Abi Williams, David W. Scott, MBChB, PhD, Randy D. Gascoyne, MD, Kazuhito Yamamoto, Wojciech Jurczak, Muhit Özcan, David Belada, Juan Miguel Bergua Burgues, Francesco Piazza, Carlo Visco, Gerardo Musuraca, MD, Sandra Margunato-Debay, Myron Czuczman, Merry Zhai, Julia Braverman, Umberto Vitolo, Grzegorz Nowakowski, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3475.
https://doi.org/10.1182/blood-2019-123948
Published: 2019
Journal Articles

Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study

Katja Weisel, Agne Paner, MD, Monika Engelhardt, MD, Fiona Taylor, Kim Cocks, Mihaela Popa-McKiver, PhD, Clara Chen, PhD BS, MS, Michele Cavo
Journal: Blood
Blood (2019) 134 (Supplement_1): 3480.
https://doi.org/10.1182/blood-2019-122232
Published: 2019
Journal Articles

A Mixed Methods Approach to Generate Meaningful Change Estimates for the EORTC QLQ-MY20

Emre Yucel, PhD MSc, MBA, BSPharm, Andrew Trigg, MSc, Kate Sully, PhD, Amelia Harper, Nicola Bonner, MSc, Nina Shah, MD, Sumeet Panjabi, PhD, Kim Cocks
Journal: Blood
Blood (2018) 132 (Supplement 1): 5912.
https://doi.org/10.1182/blood-2018-99-116746
Published: 2018
Journal Articles

Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study

Katja Weisel, MD, Agne Paner, MD, Monika Engelhardt, MD, Fiona Taylor, Kim Cocks, Ashlee Espensen, Mihaela Popa-McKiver, PhD, Clara Chen, PhD BS, MS, Michele Cavo, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2288.
https://doi.org/10.1182/blood-2018-99-112080
Published: 2018
Journal Articles

Effect of Nivolumab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma after Autologous Transplantation: Results from the Multicohort Phase 2 Checkmate 205 Study

Andreas Engert, MD, Fiona Taylor, Bryan Bennett, Clara Chen, PhD BS, MS, Kim Cocks, Jeffrey McDonald, Erin Mann, Mariana Sacchi, David Cella, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3441.
https://doi.org/10.1182/blood.V130.Suppl_1.3441.3441
Published: 2017
Journal Articles

Health Related Quality of Life Results from the Open-Label, Randomized, Phase III Endeavor Trial Evaluating Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Heinz Ludwig, Philippe Moreau, Meletios A Dimopoulos, Maria-Victoria Mateos, Martin F Kaiser, MD, Shibao Feng, Kim Cocks, Jacqueline Buchanan, Katja Weisel, MD
Journal: Blood
Blood (2016) 128 (22): 3309.
https://doi.org/10.1182/blood.V128.22.3309.3309
Published: 2016
Journal Articles

Patient Subgroup Analysis of Quality-of-Life Outcomes in Checkmate 205, a Phase 2 Study of Nivolumab in Patients with Classical Hodgkin Lymphoma

Andreas Engert, MD, Fiona Taylor, Bryan Bennett, Ishan Hirji, Kim Cocks, Jeffrey McDonald, Erin Mann, Kazunobu Kato, MD, David Cella, PhD
Journal: Blood
Blood (2016) 128 (22): 1831.
https://doi.org/10.1182/blood.V128.22.1831.1831
Published: 2016
Journal Articles

Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Versus Melphalan Plus Dexamethasone (MD) for Newly-Diagnosed Systemic AL Amyloidosis – Results From the UK Amyloidosis Treatment Trial.

Julian Gillmore, Kim Cocks, Simon DJ Gibbs, Prayman T Sattianayagam, Thirusha Lane, Helen Lachmann, Stephen Schey, James D. Cavenagh, Heather Oakervee, Gareth J Morgan, Atul B Mehta, Suzan Bourne, E. Skinner, G. Booth, Philip N Hawkins, Ashutosh D Wechalekar
Journal: Blood
Blood (2009) 114 (22): 2869.
https://doi.org/10.1182/blood.V114.22.2869.2869
Published: 2009
Journal Articles

The Addition of Thalidomide to the Induction Treatment of Newly Presenting Myeloma Patients Increases the CR Rate Which Is Likely to Translate Into Improved PFS and OS.

Gareth J Morgan, MD, PhD, Faith E Davies, MD, Walter M Gregory, Susan E Bell, Alex J Szubert, Kim Cocks, Nuria Navarro Coy, Mark T Drayson, Roger G Owen, Fiona M Ross, DPhil, Graham H Jackson, J. Anthony Child
Journal: Blood
Blood (2009) 114 (22): 352.
https://doi.org/10.1182/blood.V114.22.352.352
Published: 2009
Journal Articles

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping

David C. Johnson, Sophie Corthals, Christine Ramos, Antje Hoering, Kim Cocks, Nicholas J. Dickens, Jeff Haessler, Harmut Goldschmidt, J. Anthony Child, Sue E. Bell, Graham Jackson, Dalsu Baris, S. Vincent Rajkumar, Faith E. Davies, Brian G. M. Durie, John Crowley, Pieter Sonneveld, Brian Van Ness, Gareth J. Morgan
Journal: Blood
Blood (2008) 112 (13): 4924–4934.
https://doi.org/10.1182/blood-2008-02-140434
Published: 2008
Includes: Supplemental data
Journal Articles

Thalidomide Combinations Improve Response Rates; Results from the MRC IX Study.

Gareth J. Morgan, MD, PhD, Faith E. Davies, MD, Roger G. Owen, MD, Andrew C. Rawstron, PhD, Sue Bell, DPhil, Kim Cocks, MSc, Walter Gregory, Graham Jackson, MD, Mark T. Drayson, PhD, Matthew W. Jenner, MD, James A. Child, MD
Journal: Blood
Blood (2007) 110 (11): 3593.
https://doi.org/10.1182/blood.V110.11.3593.3593
Published: 2007
Journal Articles

Baseline Characteristics Associated with Quality of Life in CLL Patients Requiring Therapy.

Monica Else, MSc, Alastair G. Smith, MD, Sue M. Richards, DPhil, Kim Cocks, MSc, Shirley Crofts, MSc, Daniel Catovsky, MD
Journal: Blood
Blood (2007) 110 (11): 2062.
https://doi.org/10.1182/blood.V110.11.2062.2062
Published: 2007
Journal Articles

Defining Complete Response in Multiple Myeloma: Role of the Serum Free Light Chain Assay and Multiparameter Flow Cytometry.

Roger G. Owen, MD, J. Anthony Child, MD, Andy C. Rawstron, Phd, Sue Bell, Phd, Kim Cocks, Phd, Faith E. Davies, MD, Graham H. Jackson, MD, Gareth J. Morgan, MD, PhD, Mark T. Drayson, MD
Journal: Blood
Blood (2007) 110 (11): 1479.
https://doi.org/10.1182/blood.V110.11.1479.1479
Published: 2007
Journal Articles

NCRI CLL201 Trial: A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) with or without Rituximab in Previously Treated CLL.

Peter Hillmen, MBChB, PhD, Christopher Pocock, MB, BS, PhD, Dena Cohen, MSc, Kim Cocks, MSc, Hazem A. Sayala, MB, BCh, Andy Rawstron, PhD, Daniel B. Kennedy, MB, ChB, Christopher Fegan, MB, BS, Don W. Milligan, MB, ChB, Claire Dearden, MB, BS, Alexandra Smith, BSc, Emma Lindop, BSc, Andrew R. Pettitt, MB, BChir, PhD
Journal: Blood
Blood (2007) 110 (11): 752.
https://doi.org/10.1182/blood.V110.11.752.752
Published: 2007